Drugs / Ametumumab
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05684211 Comparator | Jan 2023 | colorectal cancer | Shanghai Celfuture Biotech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ametumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05684211 ↗ |
| Action | Inhibit | “A recombinant fully human anti-EGFR monoclonal antibody” NCT05684211 ↗ |
| Modality | Monoclonal antibody | “A recombinant fully human anti-EGFR monoclonal antibody” NCT05684211 ↗ |
| Target | EGFR | “A recombinant fully human anti-EGFR monoclonal antibody” NCT05684211 ↗ |